nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

19.07.2019 | Original Article – Clinical Oncology

Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients

verfasst von: Luca Nicosia, Rosario Mazzola, Michele Rigo, Vanessa Figlia, Niccolò Giaj-Levra, Giuseppe Napoli, Francesco Ricchetti, Stefanie Corradini, Ruggero Ruggieri, Filippo Alongi

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

External beam radiotherapy (EBRT) is an effective treatment option for low- and favorable intermediate-risk prostate cancer (PCa) and it is usually delivered in conventional fractionation or with moderate hypofractionation (hRT), with comparable results. In the last years, a new treatment approach with stereotactic body radiotherapy (SBRT) has shown promising results. The aim of the present study was to directly compare the toxicity and outcome between hRT and SBRT in low and favorable intermediate PCa patients.

Materials and methods

The hRT schedules were: 71.4 Gy or 74.2 Gy in 28 fractions for low- or favorable intermediate-risk PCa, respectively, while the SBRT schedules were: 35 Gy or 37.5 Gy in five fractions, for low or favorable intermediate risk, respectively. Toxicity assessment was performed according to CTCAE v5.0 grading. The International Prostatic Symptoms Score (IPSS) was also recorded.

Results

One hundred forty-nine patients were analyzed, overall 81 (54.36%) patients were low risk and 68 (45.64%) were favorable intermediate risk. Sixty-nine (46.3%) patients were treated with hypo-RT and 80 (53.7%) with SBRT. Median follow-up was 33 months (range 11–58 months). The actuarial survival rate was 98.66%. The 3-years BFS rates were 95.5% and 100% for hRT and SBRT, respectively (p = 0.051). One case (0.6%) of acute grade 3 urinary toxicity occurred in a patient with favorable intermediate risk treated with hRT. He initially suffered gross hematuria and acute urinary retention not treatable with urinary catheter, therefore a suprapubic catheter was placed and steroids were administered. No differences in acute, late or severe toxicity were detected.

Conclusion

Stereotactic body radiotherapy reported a good clinical outcome and safe toxicity profile. Results are comparable to hRT, but a longer follow-up is needed to assess the late effectiveness and toxicity.

Alongi F, Cozzi L, Arcangeli S, Iftode C, Comito T, Villa E, Lobefalo F, Navarria P, Reggiori G, Mancosu P, Clerici E, Fogliata A, Tomatis S, Taverna G, Graziotti P, Scorsetti M (2013) Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol 8(8):171. https://doi.org/10.1186/1748-717X-8-171 CrossRefPubMedPubMedCentral

Alongi F, Mazzola R, Fiorentino A, Corradini S, Aiello D, Figlia V, Gregucci F, Ballario R, Cavalleri S, Ruggieri R (2019) Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. Strahlenther Onkol 195(2):113–120. https://doi.org/10.1007/s00066-018-1338-7 CrossRefPubMed

Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M 3rd, Gottschalk A (2014) Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol 2(9):42. https://doi.org/10.1186/1748-717X-9-42 CrossRef

Arcangeli S et al (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84(5):1172–1178CrossRefPubMed

Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101CrossRefPubMed

Collins CD, Lloyd-Davies RW, Swan AV (1991) Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 3(3):127–132CrossRef

Dasu A, Toma-Dasu I (2012) Prostate alpha/beta revisited—an analysis of clinical results from 14 168 patients. Acta Oncol 51(8):963–974. https://doi.org/10.3109/0284186X.2012.719635 CrossRefPubMed

De Bari B, Arcangeli S, Ciardo D, Mazzola R, Alongi F, Russi EG, Santoni R, Magrini SM, Jereczek-Fossa BA, on the behalf of the Italian Association of Radiation Oncology (AIRO) (2016) Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treat Rev. 50:48–60. https://doi.org/10.1016/j.ctrv.2016.08.005 CrossRefPubMed

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O’Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E, CHHiP Investigators (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047–1060. https://doi.org/10.1016/s1470-2045(16)30102-4 CrossRefPubMedPubMedCentral

Fersino S, Tebano U, Mazzola R, Giaj-Levra N, Ricchetti F, Di Paola G, Fiorentino A, Sicignano G, Naccarato S, Ruggieri R, Cavalleri S, Alongi F (2017) Moderate hypofractionated postprostatectomy volumetric modulated arc therapy with daily image guidance (VMAT-IGRT): a mono-institutional report on feasibility and acute toxicity. Clin Genitourin Cancer. 15(4):e667–e673. https://doi.org/10.1016/j.clgc.2017.01.025 CrossRefPubMed

Fowler J, Chappell R, Ritter M (2001) Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4):1021–1031CrossRefPubMed

Franzese C, D’agostino G, Di Brina L, Navarria P, De Rose F, Comito T, Franceschini D, Mancosu P, Tomatis S, Scorsetti M (2019) Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer propensity-score based comparison of outcome and toxicity. Br J Radiol. 13:20190021. https://doi.org/10.1259/bjr.20190021 CrossRef

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE, ProtecT Study Group (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 375(15):1415–1424. https://doi.org/10.1056/nejmoa1606220 CrossRefPubMed

Hannan R, Tumati V, Xie XJ et al (2016) Stereotactic body radiation therapy for low and intermediate risk prostate cancer-results from a multi-institutional clinical trial. Eur J Cancer 59:142–151CrossRefPubMed

Hoffman KE et al (2014) Risk of late toxicity in men receiving dose escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88(5):1074–1084CrossRefPubMed

Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17(8):1061–1069. https://doi.org/10.1016/S1470-2045(16)30070-5 CrossRefPubMed

Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB (2016) Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol 121(2):294–298. https://doi.org/10.1016/j.radonc.2016.10.013 CrossRefPubMed

Katz AJ, Santoro M, Diblasio F et al (2013) Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 8:118CrossRefPubMedPubMedCentral

Kim MS, Kim W, Park IH, Kim HJ, Lee E, Jung JH, Cho LC, Song CW (2015) Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery. Radiat Oncol J. 33(4):265–275. https://doi.org/10.3857/roj.2015.33.4.265 (Epub 2015 Dec 30) CrossRefPubMedPubMedCentral

Kishan AU, Wang PC, Upadhyaya SK, Hauswald H, Demanes DJ, Nickols NG, Kamrava M, Sadeghi A, Kupelian PA, Steinberg ML, Prionas ND, Buyyounouski MK, King CR (2016) SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Pract Radiat Oncol 6(4):268–275. https://doi.org/10.1016/j.prro.2015.11.002 CrossRefPubMed

Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR (2019) Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open 2(2):e188006. https://doi.org/10.1001/jamanetworkopen.2018.8006 PubMed PMID: 30735235 CrossRefPubMedPubMedCentral

Kupelian P, Katz AJ, Freeman D et al (2013) Long-term efficacy of stereotactic body radiotherapy for localized prostate cancer: a multi-institutional pooled analysis. J Clin Oncol 31:abstr 9CrossRef

Lee WR et al (2016) Randomized phase III non-inferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34:JCO670448

Mantz C (2014) A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. Front Oncol 4:279CrossRefPubMedPubMedCentral

Musunuru HB, Klotz L, Vesprini D et al (2016) Comparison of contemporary treatment options for early prostate cancer: a single institution series. Austin J Radiat Oncol Cancer 2:1018

National Comprehensive Cancer Network. Prostate cancer, version 2.2019. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 18 July 2019

Oliai C, Bernetich M, Brady L, Yang J, Hanlon A, Lamond J, Arrigo S, Good M, Mooreville M, Garber B, Lanciano R (2016) Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer. J Radiat Oncol 5:187–195 Epub 2016 Jan 23 CrossRefPubMedPubMedCentral

Park Y, Park HJ, Jang WI, Jeong BK, Kim HJ, Chang AR (2018) Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01). Radiat Oncol 13(1):230. https://doi.org/10.1186/s13014-018-1182-z CrossRefPubMedPubMedCentral

Pham HT, Song G, Badiozamani K et al (2010) Five-year outcome of stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP) for patients with low-risk prostate cancer. Int J Rad Oncol Biol Phys 78:S58CrossRef

Pollack A et al (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31:3860 (JCO–2013) CrossRefPubMedPubMedCentral

Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA (2006) PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 64(4):1140–1150CrossRefPubMed

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 65(4):965–974CrossRefPubMed

Ruggieri R, Naccarato S, Stavrev P, Stavreva N, Fersino S, Giaj Levra N, Mazzola R, Mancosu P, Scorsetti M, Alongi F (2015) Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. Br J Radiol 88(1054):20140736. https://doi.org/10.1259/bjr.20140736 CrossRefPubMedPubMedCentral

Scorsetti M, Alongi F, Clerici E, Comito T, Fogliata A, Iftode C, Mancosu P, Navarria P, Reggiori G, Tomatis S, Villa E, Cozzi L (2014) Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. J Cancer Res Clin Oncol 140(10):1795–1800. https://doi.org/10.1007/s00432-014-1732-1 CrossRefPubMed

Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Miyakawa A, Murai T, Takaoka T, Hattori Y, Asai R (2015) Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol 10(6):960–964. https://doi.org/10.1097/JTO.0000000000000525 CrossRefPubMed

Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev 25(1):16–27. https://doi.org/10.1158/1055-9965.EPI-15-0578 (Epub 2015 Dec 14) CrossRef

Van As NJ, Brand D, Tree A, Ostler PJ, Chu W, Loblaw A, Ford D, Tolan SP, Jain S, Martin AS, Staffurth J, Brown S, Burnett SM, Duffton A, Griffin C, Hinder V, Morrison K, Naismith OF, Hall E, On behalf of the PACE investigators (2019) PACE: analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa). J Clin Oncol 37(7_suppl):1CrossRef

Zemplényi AT, Kaló Z, Kovács G, Farkas R, Beöthe T, Bányai D, Sebestyén Z, Endrei D, Boncz I, Mangel L (2018) Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. Eur J Cancer Care (Engl). https://doi.org/10.1111/ecc.12430 CrossRef

Zeng GG, McGowan TS, Larsen TM, Bruce LM, Moran NK, Tsao JR, MacPherson MS (2008) Calcifications are potential surrogates for prostate localization in image-guided radiotherapy. Int J Radiat Oncol Biol Phys 72(4):963–966. https://doi.org/10.1016/j.ijrobp.2008.07.021 CrossRefPubMed

Zimmermann M, Taussky D, Menkarios C et al (2016) Prospective phase II trial of once-weekly hypofractionated radiation therapy for low-risk adenocarcinoma of the prostate: late toxicities and outcomes. Clin Oncol (R Coll Radiol) 28:386–392CrossRef

Titel: Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients
verfasst von: Luca Nicosia
Rosario Mazzola
Michele Rigo
Vanessa Figlia
Niccolò Giaj-Levra
Giuseppe Napoli
Francesco Ricchetti
Stefanie Corradini
Ruggero Ruggieri
Filippo Alongi
Publikationsdatum: 19.07.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02983-3

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC

Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma

Wilms tumor-suppressing peptide inhibits proliferation and induces apoptosis of Wilms tumor cells in vitro and in vivo

Metastatic location of extensive stage small-cell lung cancer: implications for thoracic radiation

Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness

METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie